DEC 14, 2016 7:30 AM PST

Advances in modeling human diseases using induced pluripotent stem cell-derived cellular models

Speakers
  • Field Application Scientist; Cellular Dynamics
    Biography
      T.K. Feaster, PhD, is a Field Application Scientist at Cellular Dynamics International (CDI; Madison, WI), a Fujifilm company. Dr. Feaster received his PhD in Pharmacology in 2015 from Vanderbilt University for his work using human induced pluripotent stem cell-derived cardiomyocytes to investigate cardiac excitation-contraction coupling. Dr. Feaster joined CDI as a Technical Application Scientist working in the applications group where he served as the primary support liaison for cardiac products, as well as sharing responsibility for in-lab application development. He is currently a Field Application Scientist for CDI's Toxicology and Safety Pharmacology business unit.
    • Applications Scientist; Cellular Dynamics
      Biography
        Kile P. Mangan, PhD, an Applications Scientist at CDI, achieved Bachelor degrees in both Physiological Psychology and Philosophy (2000), followed by a PhD in Neuroscience (2013) from the University of Wisconsin - Madison. Dr. Mangan previously worked at Kimberly-Clark Corp., Rush Medical Center and University of Wisconsin School of Medicine. Dr. Mangan's PhD thesis work centered on a genetic absence (R43Q) epilepsy, discovering that tonic inhibitory currents were abolished within excitatory principle cortical neurons via a mutation-induced GABAergic receptor-trafficking alteration. His research further uncovered a novel, synthetic steroid treatment to re-establish the lost tonic inhibition, thereby decreasing absence seizure episode number and severity. At CDI, his work includes all aspects of CDI's neuronal products, including electrophysiological behaviors and measurements. Dr. Mangan's evaluation on neural-network integration and maturation within iPSC-derived neuronal cultures has helped push the field of MEA analysis and pharmacological screening forward to ‘disease-in-a-dish' assays.

      Abstract

      DATE: December 14, 2016
      TIME: 7:30am PT, 10:30am ET

      A major hurdle in developing relevant disease models for drug discovery is access to the healthy and diseased tissue of interest; induced pluripotent stem cell (iPSC) technology addresses this problem affording access to biologically relevant human tissues in essentially unlimited quantities. In this webinar, we will describe examples of how iPSC-derived disease cell models can be used to understand pathophysiological pathways in disease. Among the examples we will highlight are models of diseases induced in iPSC-derived cells from a healthy background; of epilepsy, Alzheimer’s and Parkinson’s diseases engineered into a healthy background; and of monogenic and idiopathic patient-derived models for cardiac diseases. We will briefly touch on current efforts aimed at generating large iPSC clone banks from disease backgrounds that will serve to expand access to human cell-based models. These human cell-based models can be used to explore the pathological phenotypes, genotype phenotype relationships, and environmental influences on a disease.


      Show Resources
      You May Also Like
      JUN 09, 2020 3:00 PM CEST
      C.E. CREDITS
      JUN 09, 2020 3:00 PM CEST
      DATE: June 9, 2020 TIME: 6am PT, 9am ET, 3pm CEST The importance of disposable plastic consumables and their overall impact on the experimental workflow of qPCR has been taken into considera...
      DEC 02, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      OCT 08, 2020 7:00 AM PDT
      C.E. CREDITS
      OCT 08, 2020 7:00 AM PDT
      DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      Loading Comments...
      Show Resources
      Attendees
      • See more